Source: PharmiWeb

Dimension Therapeutics: Ultragenyx and Dimension Announce Expiration of Hart-Scott-Rodino Waiting Period for Ultragenyx's Acquisition of Dimension

Ultragenyx and Dimension Announce Expiration of Hart-Scott-Rodino Waiting Period for Ultragenyx's Acquisition of Dimension...

Read full article »
Dimension Therapeutics's Competitors | Dimension Therapeutics's News | Dimension Therapeutics's Financials
Stay up-to-date with the latest news on Dimension Therapeutics
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Annalisa Jenkins's photo - CEO of Dimension Therapeutics

CEO

Annalisa Jenkins

CEO Approval Rating

79/100

Read more
Stay up-to-date with the latest news on Dimension Therapeutics